This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization

The control of schistosomiasis

Report of a WHO Expert Committee

World Health Organization Technical Report Series 728



World Health Organization, Geneva 1985

ISBN 92 4 120728 0

© World Health Organization 1985

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. For rights of reproduction or translation of WHO publications, in part or *in toto*, application should be made to the Office of Publications, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

ISSN 0512-3054 PRINTED IN SWITZERLAND 85/6480 – Schüler SA – 7500

CONTENTS

			Page
In	trod	uction	7
1	Eni	demiology	8
1.	1 1	The parasite	8
	1.1	1.1.1 Advances in characterization techniques	9
		1.1.2 Principal Schistosoma species that infect man	9
		1.1.2 Timepar Schistosoma species that infect man. 1.1.3 Longevity of the adult worm	12
		1.1.4 Other Schistosoma species infecting man	12
		1.1.5 The relationship between parasites and their snail intermediate	
		hosts	12
		1.1.6 Differentiation of cercariae that infect man	13
	1.2	The snail intermediate host	13
		1.2.1 Snail identification	13
		1.2.2 Laboratory maintenance of snails	15
		1.2.3 Snail ecology	16
	1.3	Current distribution of schistosomiasis	16
		1.3.1 Global aspects	18
		1.3.2 Species-specific epidemiological characteristics	21
	1.4	Man-made water resources	22
		1.4.1 Environmental and socioeconomic changes	22
		1.4.2 Effects of major water impoundments and irrigation	24
		1.4.3 Risk of schistosomiasis	25
		1.4.4 Importance of small impoundments	26
2.	Dis	ease due to schistosomiasis	27
		Schistosoma mansoni	28
		2.1.1 Pathology	28
		2.1.2 Clinical manifestations	30
		2.1.3 Effect of treatment on disease	32
	2.2	Schistosoma haematobium	33
		2.2.1 Pathology	33
		2.2.2 Clinical manifestations	35
		2.2.3 Effect of treatment on disease	37
		2.2.4 Schistosoma intercalatum	38
	2.3	Schistosoma japonicum and Asian schistosomes that infect man	38
		2.3.1 Pathology.	38
		2.3.2 Clinical manifestations	39
		2.3.3 Effect of treatment on disease	40
		2.3.4 Schistosoma mekongi	41
		2.3.5 A species of Schistosoma found in Malaysia	41
	24	Carcinoma and schistosomiasis	41
		Other conditions associated with schistosomiasis	43
	2.5	2.5.1 Bacteraemia due to Gram-negative bacteria	43
		2.5.2 Hepatitis B virus	43
		2.5.3 Nutrition and schistosomiasis.	44
	26	The immune response to schistosomiasis in man	44
	2.0		44
		2.6.1 Humoral immune response	45
		Z.O.Z Associations between disease and infiniting	43

3.1. Health education. 4 3.1.1 Behaviour, morbidity, and recognition of symptoms. 4 3.1.2 Health for all by the year 2000. 4 3.2.1 Stool examination techniques. 4 3.2.2 Urine examination techniques. 4 3.2.3 Indirect diagnostic techniques. 5 3.2.4 Miracidial hatching techniques. 5 3.2.5 Immunodiagnostic techniques. 5 3.2.5 Immunodiagnostic techniques. 5 3.3.1 Metrifonate. 5 3.3.2 Oxamniquine. 5 3.3.3 Praziquantel. 5 3.3.4 Combination drugs. 5 3.3.5 Drugs under development. 5 3.3.6 Resistance to drugs. 5 3.4.1 Available molluscicides. 5 3.4.2 Molluscicides under development. 5 3.4.3 Toxicity, mutagenicity, and carcinogenicity testing. 6 3.4.4 Resistance to molluscicides. 6 3.4.5 The market for molluscicides. 6 3.4.6 The market for molluscicides in schistosomiasis control. 6 3.4.9 Biological control. 6 3.5.1 Irrigation schemes. 6 3.5.2 Natural habitats. 6	Me	thods of control	45
3.1.1 Behaviour, morbidity, and recognition of symptoms 4 3.1.2 Health for all by the year 2000 4 3.2 Diagnostic techniques 4 3.2.1 Stool examination techniques 4 3.2.2 Urine examination techniques 5 3.2.3 Indirect diagnostic techniques 5 3.2.4 Miracidial hatching techniques 5 3.2.5 Immunodiagnostic techniques 5 3.3.1 Metrifonate 5 3.3.2 Oxamniquine 5 3.3.3 Praziquantel 5 3.3.4 Combination drugs 5 3.3.5 Drugs under development 5 3.4.1 Available molluscicides 5 3.4.2 Molluscicides under development 5 3.4.3 Toxicity, mutagenicity, and carcinogenicity testing 6 3.4.4 Resistance to molluscicides 6 3.4.5 Laboratory screening of molluscicides 6 3.4.6 The market for molluscicides 6 3.4.7 Mollusciciding costs 6 3.4.8 Future role of molluscicides in schistosomiasis control 6 3.5.1 Irrigation schemes 6 3.5.2 Natural habitats 6 3.5.3 Man-made reservoirs 6			46
3.1.2 Health for all by the year 2000. 3.2 Diagnostic techniques. 3.2.1 Stool examination techniques. 3.2.2 Urine examination techniques. 3.2.3 Indirect diagnostic techniques. 3.2.4 Miracidial hatching techniques. 3.2.5 Immunodiagnostic techniques. 3.2.6 Immunodiagnostic techniques. 3.2.7 Immunodiagnostic techniques. 3.2.8 Chemotherapy. 3.2.9 Cyamniquine. 3.3.1 Metrifonate. 3.3.2 Oxamniquine. 3.3.3 Praziquantel. 3.3.4 Combination drugs. 3.3.5 Drugs under development. 3.3.6 Resistance to drugs. 3.4.1 Available molluscicides. 3.4.2 Molluscicides under development. 3.4.3 Toxicity, mutagenicity, and carcinogenicity testing. 3.4.4 Resistance to molluscicides. 3.4.5 Laboratory screening of molluscicides. 3.4.6 The market for molluscicides. 3.4.7 Mollusciding costs. 3.4.8 Future role of molluscicides in schistosomiasis control. 3.5 Environmental management and modification. 3.5.1 Irrigation schemes. 3.5.2 Natural habitats. 3.5.3 Man-made reservoirs. 3.5.4 Environmental modification. 3.6 Sanitation and water supply. 3.6 Sanitation and water supply. 3.6 Sanitation and water supply. 3.7 Data management. 3.7 Requirements for data analysis in the control of schistosomiasis on timplementation of control. 3.8 Training. 6 Review of progress in national programmes. 7 Al Countries where S. mansoni is endemic. 4.1 Countries where S. mansoni is endemic. 4.1 Countries where S. haematobium is endemic. 4.2 Countries where S. haematobium is endemic. 4.1 Countries where S. haematobium is endemic. 4.2 Morocco. 4.2 Morocco. 4.2 United Republic of Tanzania: Zanzibar.	3.1		
3.2.1 Stool examination techniques		2.1.2 Heraviour, morbidity, and recognition of symptoms	
3.2.1 Stool examination techniques	2.2	3.1.2 Health for all by the year 2000	
3.2.2 Urine examination techniques	3.2	Diagnostic techniques	
3.2.3 Indirect diagnostic techniques 5 3.2.4 Miracidial hatching techniques 5 3.2.5 Immunodiagnostic techniques 5 3.3.1 Metrifonate 5 3.3.2 Oxamniquine 5 3.3.3 Praziquantel 5 3.3.4 Combination drugs 5 3.3.5 Drugs under development 5 3.3.6 Resistance to drugs 5 3.4.1 Available molluscicides 5 3.4.2 Molluscicides under development 5 3.4.3 Toxicity, mutagenicity, and carcinogenicity testing 6 3.4.4 Resistance to molluscicides 6 3.4.5 Laboratory screening of molluscicides 6 3.4.6 The market for molluscicides 6 3.4.7 Mollusciciding costs 6 3.4.8 Future role of molluscicides in schistosomiasis control 6 3.4.9 Biological control 6 3.5.1 Irrigation schemes 6 3.5.2 Natural habitats 6 3.5.3 Man-made reservoirs 6 3.6 Sanitation 6 3.7.1 Requirements for data analysis in the control of schistosomiasis 3.7.2 Sources of the information necessary for the preparation and implementation of control		3.2.1 Stool examination techniques	
3.2.4 Miracidial hatching techniques 5 3.2.5 Immunodiagnostic techniques 5 3.3 Chemotherapy 5 3.3.1 Metrifonate 5 3.3.2 Oxamniquine 5 3.3.3 Praziquantel 5 3.3.4 Combination drugs 5 3.3.5 Drugs under development 5 3.3.6 Resistance to drugs 5 3.4 Snail control 5 3.4.1 Available molluscicides 5 3.4.2 Molluscicides under development 5 3.4.3 Toxicity, mutagenicity, and carcinogenicity testing 6 3.4.4 Resistance to molluscicides 6 3.4.5 Laboratory screening of molluscicides 6 3.4.6 The market for molluscicides 6 3.4.7 Mollusciciding costs 6 3.4.8 Future role of molluscicides in schistosomiasis control 6 3.5.1 Irrigation schemes 6 3.5.2 Natural habitats 6 3.5.3 Man-made reservoirs 6 3.5.4 Environmental management and modification 6 3.6 Sanitation and water supply 6 3.6.1 Sanitation 6 3.6.2 Water supply 6			
3.2.5 Immunodiagnostic techniques 5 3.3.1 Metrifonate 5 3.3.2 Oxamniquine 5 3.3.3 Praziquantel 5 3.3.4 Combination drugs 5 3.3.5 Drugs under development 5 3.3.6 Resistance to drugs 5 3.4.1 Available molluscicides 5 3.4.2 Molluscicides under development 5 3.4.3 Toxicity, mutagenicity, and carcinogenicity testing 6 3.4.4 Resistance to molluscicides 6 3.4.5 Laboratory screening of molluscicides 6 3.4.6 The market for molluscicides 6 3.4.7 Mollusciding costs 6 3.4.8 Future role of molluscicides in schistosomiasis control 6 3.5.1 Irrigation schemes 6 3.5.2 Natural habitats 6 3.5.3 Man-made reservoirs 6 3.5.4 Environmental modification 6 3.6 Sanitation and water supply 6 3.6.1 Sanitation 6 3.7.2 Sources of the information necessary for the preparation and implementation of control 6 3.8 Training 6 Review of progress in national programmes 7			50
3.3.1 Metrifonate. 5 3.3.2 Oxamniquine 5 3.3.3 Praziquantel. 5 3.3.4 Combination drugs. 5 3.3.5 Drugs under development. 5 3.3.6 Resistance to drugs. 5 3.4 Snail control. 5 3.4.1 Available molluscicides. 5 3.4.2 Molluscicides under development. 5 3.4.3 Toxicity, mutagenicity, and carcinogenicity testing. 6 3.4.4 Resistance to molluscicides. 6 3.4.5 Laboratory screening of molluscicides. 6 3.4.6 The market for molluscicides. 6 3.4.7 Mollusciciding costs. 6 3.4.8 Future role of molluscicides in schistosomiasis control. 6 3.4.9 Biological control. 6 3.5.1 Irrigation schemes. 6 3.5.2 Natural habitats. 6 3.5.3 Man-made reservoirs. 6 3.5.4 Environmental modification. 6 3.6 Sanitation and water supply. 6 3.6.1 Sanitation. 6 3.6.2 Water supply. 6 3.7.1 Requirements for data analysis in the control of schistosomiasis 3.7.2 Sources of the information n			50
3.3.1 Metrifonate. 5 3.3.2 Oxamniquine. 5 3.3.3 Praziquantel. 5 3.3.4 Combination drugs. 5 3.3.5 Drugs under development. 5 3.3.6 Resistance to drugs. 5 3.4 Snail control. 5 3.4.1 Available molluscicides. 5 3.4.2 Molluscicides under development. 5 3.4.3 Toxicity, mutagenicity, and carcinogenicity testing. 6 3.4.3 Toxicity, mutagenicity, and carcinogenicity testing. 6 3.4.4 Resistance to molluscicides. 6 3.4.5 Laboratory screening of molluscicides. 6 3.4.6 The market for molluscicides. 6 3.4.7 Mollusciciding costs. 6 3.4.8 Future role of molluscicides in schistosomiasis control. 6 3.4.9 Biological control. 6 3.5.1 Irrigation schemes. 6 3.5.2 Natural habitats. 6 3.5.3 Man-made reservoirs. 6 3.5.4 Environmental modification. 6 3.6.1 Sanitation and water supply. 6 3.6.2 Water supply. 6 3.7.1 Requirements for data analysis in the control of schistosomiasis 3.7.2 Sou		3.2.5 Immunodiagnostic techniques	51
3.3.1 Metrifonate. 5 3.3.2 Oxamniquine. 5 3.3.3 Praziquantel. 5 3.3.4 Combination drugs. 5 3.3.5 Drugs under development. 5 3.3.6 Resistance to drugs. 5 3.4 Snail control. 5 3.4.1 Available molluscicides. 5 3.4.2 Molluscicides under development. 5 3.4.3 Toxicity, mutagenicity, and carcinogenicity testing. 6 3.4.4 Resistance to molluscicides. 6 3.4.5 Laboratory screening of molluscicides. 6 3.4.6 The market for molluscicides. 6 3.4.7 Mollusciciding costs. 6 3.4.8 Future role of molluscicides in schistosomiasis control. 6 3.4.9 Biological control. 6 3.5.1 Irrigation schemes. 6 3.5.2 Natural habitats. 6 3.5.3 Man-made reservoirs. 6 3.5.4 Environmental modification. 6 3.5.2 Water supply. 6 3.6.1 Sanitation 6 3.7.1 Requirements for data analysis in the control of schistosomiasis 3 3.7.2 Sources of the information necessary for the preparation and implementation of control.	3.3	Chemotherapy	51
3.3.3 Praziquantel		3.3.1 Metrifonate	53
3.3.3 Praziquantel. 5 3.3.4 Combination drugs. 5 3.3.5 Drugs under development. 5 3.3.6 Resistance to drugs. 5 3.4.1 Available molluscicides. 5 3.4.2 Molluscicides under development. 5 3.4.3 Toxicity, mutagenicity, and carcinogenicity testing. 6 3.4.4 Resistance to molluscicides. 6 3.4.5 Laboratory screening of molluscicides. 6 3.4.6 The market for molluscicides. 6 3.4.7 Mollusciciding costs. 6 3.4.8 Future role of molluscicides in schistosomiasis control. 6 3.4.9 Biological control. 6 3.5.1 Irrigation schemes. 6 3.5.2 Natural habitats. 6 3.5.3 Man-made reservoirs. 6 3.5.4 Environmental modification. 6 3.6.1 Sanitation and water supply. 6 3.6.2 Water supply. 6 3.7.1 Requirements for data analysis in the control of schistosomiasis and implementation of control. 6 3.8 Training. 6 4.1 Countries where S. haematohium is endemic. 7 4.1.1 Brazil. 7 4.2 Countries where S. haematohium		3.3.2 Oxamniquine	54
3.3.4 Combination drugs 5 3.3.5 Drugs under development 5 3.3.6 Resistance to drugs 5 3.4 Snail control 5 3.4.1 Available molluscicides 5 3.4.2 Molluscicides under development 5 3.4.3 Toxicity, mutagenicity, and carcinogenicity testing 6 3.4.4 Resistance to molluscicides 6 3.4.5 Laboratory screening of molluscicides 6 3.4.6 The market for molluscicides 6 3.4.7 Mollusciciding costs 6 3.4.8 Future role of molluscicides in schistosomiasis control 6 3.4.9 Biological control 6 3.5 Environmental management and modification 6 3.5.1 Irrigation schemes 6 3.5.2 Natural habitats 6 3.5.3 Man-made reservoirs 6 3.5.4 Environmental modification 6 3.6.1 Sanitation and water supply 6 3.6.2 Water supply 6 3.7.1 Requirements for data analysis in the control of schistosomiasis 3.7.2 Sources of the information necessary for the preparation and implementation of control 6 3.8 Training 6 4.1 Countries where S. mansoni is endemic <td></td> <td>3.3.3 Praziquantel</td> <td>55</td>		3.3.3 Praziquantel	55
3.3.5 Drugs under development 5 3.3.6 Resistance to drugs 5 3.4 Snail control 5 3.4.1 Available molluscicides 5 3.4.2 Molluscicides under development 5 3.4.3 Toxicity, mutagenicity, and carcinogenicity testing 6 3.4.4 Resistance to molluscicides 6 3.4.5 Laboratory screening of molluscicides 6 3.4.6 The market for molluscicides 6 3.4.7 Mollusciciding costs 6 3.4.8 Future role of molluscicides in schistosomiasis control 6 3.4.9 Biological control 6 3.5 Environmental management and modification 6 3.5.1 Irrigation schemes 6 3.5.2 Natural habitats 6 3.5.3 Man-made reservoirs 6 3.5.4 Environmental modification 6 3.6 Sanitation and water supply 6 3.6.1 Sanitation 6 3.6.2 Water supply 6 3.7.1 Requirements for data analysis in the control of schistosomiasis 3 3.7.2 Sources of the information necessary for the preparation and implementation of control 6 3.8 Training 6 4.1 Countries whe		3.3.4 Combination drugs	56
3.3.6 Resistance to drugs 5 3.4.1 Snail control 5 3.4.1 Available molluscicides 5 3.4.2 Molluscicides under development 5 3.4.3 Toxicity, mutagenicity, and carcinogenicity testing 6 3.4.4 Resistance to molluscicides 6 3.4.5 Laboratory screening of molluscicides 6 3.4.6 The market for molluscicides 6 3.4.7 Mollusciciding costs 6 3.4.8 Future role of molluscicides in schistosomiasis control 6 3.4.9 Biological control 6 3.5.1 Irrigation schemes 6 3.5.2 Natural habitats 6 3.5.3 Man-made reservoirs 6 3.5.4 Environmental modification 6 3.6 Sanitation and water supply 6 3.6.1 Sanitation 6 3.6.2 Water supply 6 3.7.1 Requirements for data analysis in the control of schistosomiasis 6 3.7.2 Sources of the information necessary for the preparation and implementation of control 6 3.8 Training 6 4.1 Countries where S. mansoni is endemic 7 4.1.2 Corogo 7 4.2.3 Tunisia 7		3 3 5 Drugs under development	57
3.4 Snail control. 5 3.4.1 Available molluscicides. 5 3.4.2 Molluscicides under development. 5 3.4.3 Toxicity, mutagenicity, and carcinogenicity testing. 6 3.4.4 Resistance to molluscicides. 6 3.4.5 Laboratory screening of molluscicides. 6 3.4.6 The market for molluscicides. 6 3.4.7 Mollusciciding costs. 6 3.4.8 Future role of molluscicides in schistosomiasis control. 6 3.4.9 Biological control. 6 3.5.1 Irrigation schemes. 6 3.5.2 Natural habitats. 6 3.5.3 Man-made reservoirs. 6 3.5.4 Environmental modification. 6 3.6.1 Sanitation and water supply. 6 3.6.2 Water supply. 6 3.7.1 Requirements for data analysis in the control of schistosomiasis 3.7.2 Sources of the information necessary for the preparation and implementation of control. 6 3.8 Training. 6 Review of progress in national programmes. 7 4.1 Countries where S. mansoni is endemic. 7 4.2.1 Congo. 7 4.2.2 Morocco. 7 4.2.3 Tunisia. 7 <t< td=""><td></td><td>3.3.6 Resistance to drugs</td><td>58</td></t<>		3.3.6 Resistance to drugs	58
3.4.1 Available molluscicides 5 3.4.2 Molluscicides under development 5 3.4.3 Toxicity, mutagenicity, and carcinogenicity testing 6 3.4.4 Resistance to molluscicides 6 3.4.5 Laboratory screening of molluscicides 6 3.4.6 The market for molluscicides 6 3.4.7 Mollusciciding costs 6 3.4.8 Future role of molluscicides in schistosomiasis control 6 3.4.9 Biological control 6 3.5 Environmental management and modification 6 3.5.1 Irrigation schemes 6 3.5.2 Natural habitats 6 3.5.3 Man-made reservoirs 6 3.5.4 Environmental modification 6 3.6 Sanitation and water supply 6 3.6.1 Sanitation 6 3.7.1 Requirements for data analysis in the control of schistosomiasis 3.7.1 Requirements for data analysis in the control of schistosomiasis 3.7.2 Sources of the information necessary for the preparation and implementation of control 6 3.8 Training 6 Review of progress in national programmes 7 4.1 Countries where S. mansoni is endemic 7 4.2.1 Congo 7	3 /	Snail control	-
3.4.2 Molluscicides under development	J. ⊣	2.4.1 Available melluscicides	
3.4.3 Toxicity, mutagenicity, and carcinogenicity testing		2.4.1 Mallyspicides under development	
3.4.4 Resistance to molluscicides			
3.4.5 Laboratory screening of molluscicides		3.4.5 Toxicity, mutagenicity, and carcinogenicity testing	-
3.4.6 The market for molluscicides		3.4.4 Resistance to molluscicides	
3.4.7 Mollusciciding costs		3.4.5 Laboratory screening of molluscicides	
3.4.8 Future role of molluscicides in schistosomiasis control. 3.4.9 Biological control		3.4.6 The market for molluscicides	
3.4.9 Biological control		3.4.7 Mollusciciding costs	
3.5 Environmental management and modification 6 3.5.1 Irrigation schemes 6 3.5.2 Natural habitats 6 3.5.3 Man-made reservoirs 6 3.5.4 Environmental modification 6 3.6 Sanitation and water supply 6 3.6.1 Sanitation 6 3.6.2 Water supply 6 3.7 Data management 6 3.7.1 Requirements for data analysis in the control of schistosomiasis 3.7.2 Sources of the information necessary for the preparation and implementation of control 6 3.8 Training 6 Review of progress in national programmes 7 4.1 Countries where S. mansoni is endemic 7 4.2 Countries where S. haematobium is endemic 7 4.2.1 Congo 7 4.2.2 Morocco 7 4.2.3 Tunisia 7 4.2.4 United Republic of Tanzania: Zanzibar 7 4.3 Tunisia 7 4.2.4 United Republic of Tanzania: Zanzibar 7 4.3 Tunisia 7 4.4.4 United Republic of Tanzania: Zanzibar 7 4.5 Tunisia 7 4.5 Tunisia 7 4.6 Tunisia 7 4.7 Tunisia 7 4.2.4 United Republic of Tanzania: Zanzibar 7 4.5 Tunisia 7 4.5 Tunisia 7 4.5 Tunisia 7 4.6 Tunisia 7 4.7 Tunis		3.4.8 Future role of molluscicides in schistosomiasis control	62
3.5.1 Irrigation schemes 6 3.5.2 Natural habitats 6 3.5.3 Man-made reservoirs 6 3.5.4 Environmental modification 6 3.6 Sanitation and water supply 6 3.6.1 Sanitation 6 3.6.2 Water supply 6 3.7 Data management 6 3.7.1 Requirements for data analysis in the control of schistosomiasis 6 3.7.2 Sources of the information necessary for the preparation and implementation of control 6 3.8 Training 6 Review of progress in national programmes 7 4.1 Countries where S. mansoni is endemic 7 4.2.1 Congo 7 4.2.2 Morocco 7 4.2.3 Tunisia 7 4.2.4 United Republic of Tanzania: Zanzibar 7		3.4.9 Biological control	
3.5.2 Natural habitats	3.5	Environmental management and modification	6.
3.5.2 Natural habitats		3.5.1 Irrigation schemes	63
3.5.3 Man-made reservoirs 6 3.5.4 Environmental modification 6 3.6 Sanitation and water supply 6 3.6.1 Sanitation 6 3.6.2 Water supply 6 3.7 Data management 6 3.7.1 Requirements for data analysis in the control of schistosomiasis 6 3.7.2 Sources of the information necessary for the preparation and implementation of control 6 3.8 Training 6 Review of progress in national programmes 7 4.1 Countries where S. mansoni is endemic 7 4.2.1 Congo 7 4.2.2 Morocco 7 4.2.3 Tunisia 7 4.2.4 United Republic of Tanzania: Zanzibar 7		3.5.2 Natural habitats	64
3.5.4 Environmental modification		3.5.3 Man-made reservoirs.	64
3.6 Sanitation and water supply			6.
3.6.1 Sanitation	3.6		6:
3.6.2 Water supply	5.0		
3.7 Data management			
3.7.1 Requirements for data analysis in the control of schistosomiasis 3.7.2 Sources of the information necessary for the preparation and implementation of control	27		
3.7.2 Sources of the information necessary for the preparation and implementation of control	3.7		
implementation of control 66 3.8 Training 66 Review of progress in national programmes 76 4.1 Countries where S. mansoni is endemic 76 4.1.1 Brazil 76 4.2 Countries where S. haematobium is endemic 77 4.2.1 Congo 77 4.2.2 Morocco 77 4.2.3 Tunisia 76 4.2.4 United Republic of Tanzania: Zanzibar 77		2.7.2 Sources of the information processory for the properties and	U.
3.8 Training 60 Review of progress in national programmes 70 4.1 Countries where S. mansoni is endemic 70 4.1.1 Brazil 70 4.2 Countries where S. haematobium is endemic 71 4.2.1 Congo 72 4.2.2 Morocco 73 4.2.3 Tunisia 74 4.2.4 United Republic of Tanzania: Zanzibar 73		3.7.2 Sources of the information necessary for the preparation and	
Review of progress in national programmes 76 4.1 Countries where S. mansoni is endemic 76 4.1.1 Brazil 76 4.2 Countries where S. haematobium is endemic 77 4.2.1 Congo 77 4.2.2 Morocco 77 4.2.3 Tunisia 76 4.2.4 United Republic of Tanzania: Zanzibar 78	2.0	implementation of control	
4.1 Countries where S. mansoni is endemic. 76 4.1.1 Brazil. 76 4.2 Countries where S. haematobium is endemic. 7 4.2.1 Congo. 7 4.2.2 Morocco. 7 4.2.3 Tunisia. 7 4.2.4 United Republic of Tanzania: Zanzibar. 7	3.8	I raining	05
4.1 Countries where S. mansoni is endemic. 76 4.1.1 Brazil. 76 4.2 Countries where S. haematobium is endemic. 7 4.2.1 Congo. 7 4.2.2 Morocco. 7 4.2.3 Tunisia. 7 4.2.4 United Republic of Tanzania: Zanzibar. 7			
4.1.1 Brazil 70 4.2 Countries where S. haematobium is endemic 71 4.2.1 Congo 72 4.2.2 Morocco 73 4.2.3 Tunisia 74 4.2.4 United Republic of Tanzania: Zanzibar 75	Rev	view of progress in national programmes	
4.2 Countries where S. haematobium is endemic. 7. 4.2.1 Congo. 7. 4.2.2 Morocco. 7. 4.2.3 Tunisia. 7. 4.2.4 United Republic of Tanzania: Zanzibar. 7.	4.1	Countries where S. mansoni is endemic	70
4.2.1 Congo			70
4.2.1 Congo	4.2	Countries where S. haematobium is endemic	72
4.2.2 Morocco		4.2.1 Congo	72
4.2.3 Tunisia		4.2.2 Morocco	73
4.2.4 United Republic of Tanzania: Zanzibar			. 74
			7:
	4.3	Countries where both S. haematobium and S. mansoni are endemic	76

4.3.1 Egypt	76	
4.3.2 Mali	78	
4.3.3 Sudan	78	
4.4 Countries where S. japonicum is endemic	79	
4.4.1 China	79	
4.4.2 Philippines	80	
5. A strategy for morbidity control	81	
5.1 Operational approaches	82	
5.1.1 Operational phases	83	
5.1.2 Types of operational approach	83	
5.2 Operational components	84	
5.2.1 Health education.	84	
5.2.2 Delivery systems for chemotherapy	85	
5.2.3 Water supply	88	
5.2.4 Snail control.	88	
5.3 A primary health care strategy to control morbidity due to schisto-	00	
somiasis	89	
5.3.1 Tasks of the primary health care worker	90	
5.3.2 Health education	91	
5.3.3 Diagnosis of schistosomiasis at the primary health care level	91	
5.3.4 Chemotherapy	92	
5.3.5 Snail control	92	
5.3.6 Support systems for primary health care	92	
5.3.7 Linkages between primary health care and development pro-		
grammes	93	
5.4 Factors influencing the choice of operational approaches	93	
5.4.1 Available control approaches	93	
5.4.2 The limitations of operational phases	94	
5.4.3 Agricultural development areas	95	
5.4.4 Urban areas	95	
5.4.5 Personnel and political commitment	95	
5.4.6 Costing base	95	
5.5 Maintenance and evaluation	96	
5.5.1 Maintenance of control	97	
5.5.2 Evaluation of control	97	
5.5.3 Applied field research	100	
5.6 Intersectoral cooperation	100	
5.7 Assessment of the economic impact of schistosomiasis	101	
6. Conclusions.	102	
7. Recommendations	104	
7.1 General recommendations	104	
7.2 Technical recommendations	105	
Acknowledgements	107	
References	109	
Annex 1. Indices for use in schistosomiasis control programmes	110	
Annex 2. Optional chemotherapeutic approaches		

WHO EXPERT COMMITTEE ON THE CONTROL OF SCHISTOSOMIASIS

Geneva, 8-13 November 1984

Members

- Professor M. A. Amin, Ministry of Health and Social Welfare, Khartoum, Sudan Professor Z. Andrade, Gonçalo Moniz Research Centre, Oswaldo Cruz Foundation, Salvador, Bahia, Brazil
- Dr S.M. El Hak, Endemic Diseases Control Department, Ministry of Health, Cairo, Egypt
- Dr P. Jordan, Medical Research Council, National Institute for Medical Research, London, England
- Professor Mao Shou-Pai, Institute of Parasitic Diseases, China National Centre for Preventive Medicine, Shanghai, People's Republic of China
- Professor E.H. Michelson, Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, School of Medicine, Bethesda, MD, USA (*Rapporteur*)
- Professor A.B.O.O. Oyediran, Department of Preventive and Social Medicine, College of Medicine, University of Ibadan, University College Hospital, Ibadan, Nigeria
- Professor A. Prata, Department of Tropical Medicine and Nutrition, University of Brasilia, Brasilia, Brazil (*Chairman*)
- Dr D.H.G. Wegner, formerly, Medical Department, Bayer Pharma Research Centre, Wuppertal, Federal Republic of Germany

Representative of other organizations

Dr B. Liese, Population, Health and Nutrition Department, The World Bank, Washington, DC, USA

Secretariat

- Dr J.A. Cook, Program in Tropical Disease Research, The Edna McConnell Clark Foundation, New York, NY, USA (Temporary Adviser)
- Dr A. Davis, Director, Parasitic Diseases Programme, WHO, Geneva, Switzerland
- Professor E.G. Garcia, Department of Parasitology, Institute of Public Health, University of the Philippines, Manila, Philippines (*Temporary Adviser*)
- Dr N. Katz, Laboratory for Schistosomiasis, René Rachou Research Centre, Oswaldo Cruz Foundation, Belo Horizonte, Minas Gerais, Brazil (Temporary Adviser)
- Dr K. E. Mott, Chief, Schistosomiasis and other Trematode Infections, Parasitic Diseases Programme, WHO, Geneva, Switzerland (Secretary)

THE CONTROL OF SCHISTOSOMIASIS

Report of a WHO Expert Committee

A WHO Expert Committee on the Control of Schistosomiasis met in Geneva from 8 to 13 November 1984. Dr S.K. Litvinov, Assistant Director-General, opened the meeting on behalf of the Director-General.

INTRODUCTION

During the five years since the meeting of the WHO Expert Committee on the Epidemiology and Control of Schistosomiasis (19) there have been changes in the priorities and operational approaches adopted, since the immediate aim is now to control the morbidity due to schistosomiasis rather than to control its transmission. Advances have occurred in parasitological diagnostic techniques, chemotherapy, and our understanding of the human ecology and epidemiology of schistosomiasis, and this new knowledge is being incorporated into national control programmes.

Programmes to eradicate schistosomiasis or eliminate its transmission by multiple, integrated, intervention techniques are proving to be beyond the human and financial resources of most endemic countries and the objectives of such programmes will only be achieved in the long-term. However, a reduction in disease due to schistosomiasis is now a feasible objective that is based on sound epidemiological principles and it is an objective that can be achieved within the limitations of most endemic countries. Since the epidemiology of schistosomiasis varies from one endemic country to another, the managerial and operational structures of schistosomiasis control programmes will also vary. The simplicity of the diagnostic techniques, the safety and ease of administering oral antischistosomal drugs, the use of snail control measures based on specific epidemiological criteria, and precise methods of data collection and analysis, mean that schistosomiasis control activities can be adapted to suit any level of the health care delivery system. In primary health care programmes, it can now be safely anticipated that schistosomiasis control activities to reduce morbidity will be successful.

The strategy of morbidity control focuses on the population of an endemic country. Schistosomiasis is caused by the insanitary habits of man. Schistosomiasis is acquired by man as he performs necessary daily activities associated with fresh water—working, bathing, washing, fishing, and recreation. The disease condition related to schistosomiasis is caused by heavy infections. Health education as part of morbidity control is important in helping the population to modify behaviour to prevent the disease, to understand the meaning of health in contrast to disease, to recognize the symptoms of schistosomiasis, and to use appropriately the available health facilities; health education should also encourage community involvement in control programmes with a view to social action.

The success of intervention measures that have a direct impact on morbidity such as chemotherapy, water supply and sanitation, environmental management, and environmental modification all require the active participation of the population. The new approach to schistosomiasis control emphasizes collaboration and implementation at the primary health care level in preference to the combined use of different intervention methods.

The Expert Committee recognized that the organizational, managerial, and operational aspects of control are the major areas where progress can be made in the future.

This report stresses the importance and feasibility of reducing morbidity in schistosomiasis control programmes using available methods and resources.

1. EPIDEMIOLOGY

1.1 The parasite

Much of the recent work on the taxonomy of schistosome parasites has focused on the use of experimental methods to assist in the characterization of species and strains. The need to define and identify accurately schistosome genotypes has stimulated this research. Many observations, both in the field and in the laboratory, have shown that strains of a single species from different geographical areas may display marked differences in their biological characteristics, implying that genetic diversity exists within the genus *Schistosoma*.

8

预览已结束, 完整报告链接和二维码如下

